11 studies found for:    PRO-140
Show Display Options
Rank Status Study
1 Recruiting A Randomized, Double-blind, Placebo-controlled Trial, Followed by Single-arm Treatment of PRO 140 in Combination w/ Optimized Background Therapy in Treatment-Experienced HIV Subjects
Condition: HIV
Interventions: Drug: PRO 140;   Drug: Placebo;   Drug: Optimized Background Regimen
2 Recruiting An Extension of Protocol PRO 140_CD01 TS Study
Conditions: HIV;   Human Immunodeficiency Virus
Intervention: Drug: PRO 140 350mg weekly SQ injection.
3 Recruiting Treatment Substitution With PRO 140 Monotherapy in Adult Subjects With HIV-1 Infection
Conditions: HIV;   Human Immunodeficiency Virus
Intervention: Drug: PRO 140 350mg weekly SQ injection.
4 Completed Safety and Tolerability of PRO 140 in HIV Uninfected Male Volunteers
Condition: HIV Infections
Intervention: Drug: PRO 140
5 Completed
Has Results
PRO 140 by IV Administration in Adults With HIV-1 Infection
Condition: HIV Infections
Interventions: Drug: PRO 140;   Drug: Placebo
6 Withdrawn PRO 140 for Human Immunodeficiency Virus Infection
Condition: HIV
Intervention: Biological: PRO 140
7 Not yet recruiting Study of PRO 140 for Prophylaxis of Acute GVHD in Patients With AML or MDS Undergoing Allogeneic Stem-Cell Transplant.
Conditions: Graft vs Host Disease;   Leukemia, Myeloid, Acute;   Myelodysplastic Syndromes
Interventions: Drug: PRO 140;   Drug: Placebo
8 Recruiting PRO 140 for Human Immunodeficiency Virus
Condition: HIV
Intervention: Biological: PRO 140
9 Completed
Has Results
Study of PRO 140 by Subcutaneous Administration in Adult Subjects With HIV -1 Infection
Conditions: HIV -1 Infection;   HIV Infections
Interventions: Drug: PRO 140 (humanized monoclonal antibody to CCR5);   Drug: Placebo Comparator
10 Recruiting A Trial of Observed Long-acting, Anti-HIV Treatment With a Monoclonal CCR5 Antibody (PRO 140) as an Adjunct to a New, Optimized, Oral Antiretroviral Regimen in HIV-infected Injection Drug Users With Viral Rebound and Documented Poor Adherence
Condition: HIV
Interventions: Drug: PRO 140;   Drug: Placebo
11 Temporarily not available An Expanded Access Protocol for a Single Subject Who Has Completed 24-Weeks of Treatment in PR0140_CD02 Study
Condition: HIV
Intervention: Drug: PRO 140

Indicates status has not been verified in more than two years